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Background: The purpose of the study was to characterize histological response to chemotherapy of hepatic
colorectal metastases (HCRM), evaluate efficacy of different chemotherapies on histological response, and determine
whether tumor regression grading (TRG) of HCRM predicts clinical outcome.
Patients and methods: TRG was evaluated on 525 HCRM surgically resected from 181 patients, 112 pretreated
with chemotherapy. Disease-free survival (DFS) and overall survival (OS) were correlated to TRG.
Results: Tumor regression was characterized by fibrosis overgrowing on tumor cells, decreased necrosis, and tumor
glands (if present) at the periphery of HCRM. With irinotecan/5-fluorouracil (5-FU), major (MjHR), partial (PHR), and no
(NHR) histological tumor regression were observed in 17%, 13%, and 70% of patients, respectively. With oxaliplatin/
5-FU, MjHR, PHR, and NHR were observed in 37%, 45%, and 18% of patients, respectively. Five patients, treated
with oxaliplatin, had complete response in all their metastases. MjHR was associated with an improved 3-year DFS
compared with PHR or NHR. MjHR and PHR were associated with an improved 5-year OS compared with NHR.
Conclusion: Histological tumor regression of HCRM to chemotherapy corresponds to fibrosis overgrowth and not to
increase of necrosis. TRG should be considered when evaluating efficacy of chemotherapy for HCRM. Histological
tumor regression was most common among oxaliplatin-treated patients and associated with better clinical outcome.
Key words: colorectal cancer, irinotecan, oxaliplatin, pathological response to chemotherapy, sinusoidal obstruction
syndrome, tumor regression grade
introduction
Approximately 60% of patients with colorectal cancer develop
lymph node or distant metastases. The liver is the initial distant
metastatic site in30% of them. Five-year survival of 30%–60%
can be achieved if the metastases are totally removed [1–4].
Unfortunately, most patients are poor candidates for liver
surgery, mainly due to the high number of hepatic nodules,
their size, or their location.
Over the last decade, combined chemotherapy regimens
including irinotecan and oxaliplatin have markedly improved
the response rate and the survival. Several groups apply these
chemotherapies preoperatively to reduce the size of hepatic
colorectal metastases (HCRM) and to render resectable patients
who are initially unresectable [5–8]. Moreover, in patients with
advanced disease, the neo-adjuvant treatment may allow the
identification of a subgroup who could benefit from a more
aggressive approach [9, 10].
The efficacy of preoperative chemotherapy is generally
assessed by radiological evaluation. The radiological
response according to Response Evaluation Criteria in Solid
Tumors [11, 12] corresponds to the reduction in the number
and size of metastases—essentially a tumor shrinkage.
Preoperative radiology, however, has been shown to
overestimate downstaging of the tumor [13, 14], and
histology remains the best way of assessing residual tumor
viability. Moreover, in tumors such as in breast cancer [14]
and osteosarcoma [15], histological response to preoperative
chemotherapy is directly correlated with disease-free survival
(DFS) and overall survival (OS). In gastrointestinal cancers,
the correlation between histological response to preoperative
radiotherapy and/or chemotherapy and clinical outcome
has been investigated in esophageal [16] and rectal
carcinomas [17, 18], but little is known concerning
HCRM.
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The objectives of this study were (i) to define histological
criteria of response to neo-adjuvant chemotherapy and to
establish a histological tumor regression grading (TRG) system
for HCRM, (ii) to evaluate the degree of histological response
to different types of neo-adjuvant chemotherapy regimens,
and (iii) to assess if TRG of HCRM has a clinical prognostic
significance in terms of tumor recurrence or OS.
patients and methods
patients
All patients (n = 196) with colorectal carcinoma who underwent first hepatic
resection for metastases confined to the liver at the University Hospital,
Geneva, Switzerland (n = 99), and at the Hoˆpital Cochin, Paris, France
(n = 97), from 1994 to 2003 were included. The last clinical follow-up was in
December 2005. The study was in accordance with the Helsinki Declaration
of the World Medical Association. Adequate pathological material was
available for 181 patients (Table 1); 15 were excluded because of incomplete
surgical resection and/or insufficient tissue for morphological evaluation.
The median age of the patients was 66 years (range 35–82). Surgical resection
was the only treatment of HCRM in 69 patients (with 120 HCRM). One
hundred and twelve patients (with 405 HCRM) received chemotherapy
before surgery. Complete clinical follow-up were available for 106 of the
112 patients (94.6%) pretreated with chemotherapy. DFS or OS was
calculated from surgery to diagnosis of progressive disease or death,
respectively, to the most recent follow-up visit.
pathological assessment and TRG
All archival slides (from formalin-fixed paraffin-embedded tissue) of
HCRM and non-tumor tissue distant from the tumor were reviewed. The
hepatectomy specimens were sectioned in 0.5-cm-thick slices. All the HCRM
radiologically known before chemotherapy were macroscopically localized
and sampled. In patients with multiple metastases, each single lesion was
thus included for analysis. Samples from HCRM, whose diameters ranged
from 0.2 to 16 cm, were systematically taken for histology from one side to
the other of the tumor, with at least one sample per centimeter. Both the
center to the periphery of HCRM was thus largely sampled. To avoid
discrepancy, all slides were examined together at the multihead microscope
by two pathologists (LR-B and BT). Tumor regression was scored for
each HCRM according to the scheme from Mandard et al [16] for the
assessment of pathologically documented response after preoperative
radiotherapy and chemotherapy in esophageal carcinomas, modified for
liver metastases. This score identifies five TRGs on the basis of the presence
of residual tumor cells and the extent of fibrosis (Figure 1). TRG1
corresponded to absence of tumor cells replaced by abundant fibrosis; TRG2
to rare residual tumor cells scattered throughout abundant fibrosis; TRG3 to
more residual tumor cells throughout a predominant fibrosis; TRG4 to
large amount of tumor cells predominating over fibrosis; and TRG5 most
exclusively to tumor cells without fibrosis. The percentage of HCRM surface
interested by necrosis was also graded: grade 0 corresponded to an absence
of necrosis, grade 1 to <25% of surface, grade 2 to 25%–50% of surface,
grade 3 to 50%–75% of surface, and grade 4 to >75% of surface. Patients
with multiple HCRM who showed different TRG or necrosis grade between
their metastases were categorized according to the morphological aspect
of the worse metastasis (highest TRG). The distribution of viable tumor
cells (predominantly located in the center of the tumor, at the periphery,
or in equal amounts in the center and in the periphery) and acellular mucin
regarded as a form of tumor response (<25%, 25%–50%, and >50% of
the HCRM surface) were also recorded. For the non-tumoral liver,
histological features, notably the severity of sinusoidal lesions, were
evaluated according to the characteristics and score described in our
previous publication [19].
statistics
Statistical analysis was performed using the SPSS software (SPSS 10.0;
SPSS Inc., Chicago, IL). The chi-square test was used for categorical data
distributed between two groups. When there were more than two groups of
variables, the correlation was assessed using the non-parametric Kruskall–
Wallis test. Survival curves were calculated with the Kaplan–Meier method
and the influence of covariates was assessed in a univariate analysis with
Table 1. Patients and tumor characteristics
Parameter No. of patients (%)
(N = 181)
Occurrence of metastases
Metachronous 86 (47.5)
Synchronous 95 (52.5)
Sex
Male 121 (66.9)
Female 60 (33.1)
Type of resection
Right 87 (48.2)
Left 36 (19.9)
Segmental 47 (25.9)
Wedge 11 (6)
Vascular exclusiona during surgery 65 (35.9)
Portal embolization before surgery 11 (6)
Treatment
Surgery only 69 (38.1)
Neo-adjuvant chemotherapy + surgery 112 (61.9)
No. of metastases, No. of patients (%)
1 70 (38.7)
2–3 42 (23.2)
‡4 69 (38.1)
aPringle’s maneuver or vascular total exclusion.
TRG1TRG2
TRG5 TRG4 TRG3 
Figure 1. Tumor regression grade (TRG) scoring system. TRG1, absence
of residual cancer and large amount of fibrosis; TRG2, rare residual cancer
cells scattered throughout the fibrosis; TRG3, more residual tumor cells
but fibrosis predominates; TRG4, residual cancer cells predominate over
fibrosis; and TRG5, no signs of regression. Black area: tumor cells; gray
area: necrotic area; fibrils: fibrosis.
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the log-rank test. We used a Cox proportional hazards model to test the
influence on DFS and OS of all covariates found to be significant in the
univariate analysis. A P value of <0.05 was considered statistically significant.
results
pathological characteristics of HCRM
Patients and tumoral characteristics are summarized in Table 1.
Histologically, some HCRM had a high percentage of viable
tumor cells—usually with a high amount of dirty tumor
necrosis—occasionally intermingled with minimal fibrosis.
Other HCRM were characterized by moderate or major fibrosis,
largely or completely replacing both necrosis and tumor glands
(Figure 1).
In patients with more than one metastasis (111 of 181), the
morphology of the metastases within the same patient was
similar, with TRG being equal between HCRM or within one
grade range in 99 (90%) patients. The variability of TRG
between metastases was in a range of two grades in only
12 (10%) patients. Predominant colloid changes (>50% of
the surface) were rarely observed (8%).
Tumor glands, when present, predominated mainly at the
periphery in 373 HCRM (71%) and were rarely located at
the center in 10 HCRM (2%). Tumor glands were present on
the surface of the tumor in 142 HCRM (27%).
HCRM necrosis and TRG and association with
preoperative chemotherapy
The percentage of HCRM surface occupied by necrosis was
significantly lower in patients treated by preoperative
chemotherapy (n = 112) compared with HCRM of patients
treated with surgery alone (n = 69) and was different according
to the regimen of neo-adjuvant chemotherapy (Table 2).
Necrosis remained high in patients who received 5-fluorouracil
(5-FU) monotherapy (n = 30) and was not significantly different
from HCRM of patients who underwent surgery alone
(n = 69) (P > 0.05). In contrast, patients who received
irinotecan/5-FU (n = 23), oxaliplatin/5-FU (n = 38), or
oxaliplatin/irinotecan/5-FU (n = 21) had a significantly lower
necrosis compared with patients treated with 5-FU or surgery
alone (P < 0.0001).
The TRG of HCRM in patients treated by neo-adjuvant
chemotherapy was significantly lower than TRG of patient
treated with surgery alone (P < 0.0001). There were,
however, significant differences according to the regimen of
chemotherapy (Table 3). Three groups could be distinguished.
The first group was made of patients with HCRM showing
TRG4 or TRG5; this group was categorized as having no
histological tumor regressive or response changes (NHR). The
patients in this group had been treated with surgery alone
without preoperative chemotherapy or with preoperative
chemotherapy. A second group was made of patients with
HCRM showing TRG3: this group was categorized as having
partial histological tumor response (PHR). Finally, a third
group was made of patients with HRCM showing TRG2 and
TRG1: this group was categorized as having major or complete
histological tumor response (MjHR). PHR or MjHR were
observed in >80% of the patients treated by oxaliplatin/5-FU
or oxaliplatin/irinotecan/5-FU (Table 3). In contrast, only
30.4% of the patients treated with irinotecan/5-FU had PHR
or MjHR (P < 0.001), and with 5-FU alone, only 26.7% had a
PHR or MjHR (P < 0.001) (Table 3).
Seventeen of the 112 (15%) patients who received
preoperative chemotherapy [representing 44 of 405 (11%)
HCRM] had at least one HCRM showing a complete
histological response without residual tumor (TRG1). Thirteen
of these 17 patients had received oxaliplatin-based treatments:
five had a TRG1 in all of their HCRM, while eight had a
complete response (TRG1) in some HCRM and residual tumor
glands (TRG2) in the remaining HCRM. Two of the 17 patients
had been treated with 5-FU alone and the remaining two with
irinotecan/5-FU; most of the HCRM in these patients had
a TRG2.
TRG and tumor size or sinusoidal obstruction
syndrome
There was no significant correlation between the diameter of
the HCRM and the TRG (P = 0.126) or with the percentage
of necrosis (P = 0.074). Among 405 HCRM treated with
preoperative chemotherapy, 172 measured <1 cm (<0.5 cm,
n = 58; 0.6–1 cm, n = 114); 41 (23.8%) had no residual tumor
cells (TRG1); and 131 (76.2%) had persistent viable tumor
glands, of which 43 (25%) had a large amount of viable tumor
cells (TRG4 or TRG5). Among the 233 HCRM treated with
neo-adjuvant chemotherapy measuring >1 cm, three HCRM
Table 2. Grade of HCRM necrosis in patients treated by surgery alone or by
neo-adjuvant chemotherapies and surgery for colorectal liver metastases
Grade
of
necrosis
Surgery
(n = 69)
5-FU
(n = 30)
Irinotecan +
5-FU
(n = 23)
Oxaliplatin +
5-FU
(n = 38)
Oxaliplatin +
irinotecan +
5-FU
(n = 21)
0–1 9 (13%) 8 (27%) 12 (52%) 25 (66%) 12 (57%)
2 31 (45%) 11 (36%) 9 (39%) 8 (21%) 5 (24%)
3–4 29 (42%) 11 (37%) 2 (9%) 5 (13%) 4 (19%)
0–1, 0–25% of HCRM surface interested by necrosis; 2, 25–50% of surface
interested by necrosis; 3–4, >50% of surface interested by necrosis. HCRM,
hepatic colorectal metastases; 5-FU, 5-fluorouracil.
Table 3. HCRM TRG in patients treated by surgery alone or by
neo-adjuvant chemotherapy and surgery for colorectal liver metastases;
TRG1, 17 patients; TRG2, 10 patients
TRG Surgery
(n = 69)
5-FU
(n = 30)
Irinotecan +
5-FU
(n = 23)
Oxaliplatin +
5-FU
(n = 38)
Oxaliplatin +
Irinotecan +
5-FU
(n = 21)
1–2 (MjHR) 0 (0%) 2 (7%) 4 (17%) 14 (37%) 7 (33%)
3 (PHR) 0 (0%) 6 (20%) 3 (13%) 17 (45%) 10 (48%)
4–5 (NHR) 69 (100%) 22 (73%) 16 (70%) 7 (18%) 4 (19%)
HCRM, hepatic colorectal metastases; TRG, tumor regression grade; 5-FU,
5-fluorouracil; MjHR, major histological tumor response; PHR, partial
histological tumor response; NHR, no histological tumor response.
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(all <2 cm) had no residual tumor cells. All the others had
viable tumor cells.
There was no correlation between the degree of tumor
regression in HCRM and the severity of sinusoidal obstruction
syndrome (SOS) lesions in the liver parenchyma (P > 0.05).
TRG as a prognostic factor for DFS and OS in
patients treated with preoperative chemotherapy
Results on survival of patients treated with preoperative
chemotherapy are illustrated in Figures 2 and 3. In patients with
MjHR, the 1-, 3-, and 5-year DFS rates were 78%, 49%, and
38%, respectively. In patients with PHR, the 1-, 3-, and 5-year
DFS rates were 58%, 37%, and 37%, respectively. In patients
with NHR, the 1-, 3-, and 5-year DFS rates were 53%, 18%, and
15%, respectively. By univariate analysis, the 3-year DFS was
significantly higher in patients with MjHR compared with
patients with PHR or NHR (log-rank P = 0.0014). The 5-year
DFS was significantly higher in patients with MjHR and PHR
compared with patients with NHR (log-rank P = 0.008).
The 5-year OS was 41% in patients with MjHR and 38% in
patients with PHR compared with 9% in patients with NHR.
The 5-year OS was significantly higher in patients with MjHR or
PHR compared with patients with NHR (log-rank P = 0.0003
and P = 0.0019, respectively).
For multivariate analysis, we included the following factors:
patients age, number of metastases, size of the largest metastasis,
total size of the metastases, TRG, synchronous versus
metachronous HCRM, and chemotherapy. We found that
TRG was an independent prognostic factor for 5-year DFS [P =
0.001; hazard ratio = 0.713; 95% confidence interval (CI) 0.517–
0.982] and OS (P = 0.004; hazard ratio = 0.550; 95% CI 0.366–
0.829). The size of the largest metastasis was also an independent
prognostic factor for 5-year DFS (P = 0.001; hazard ratio =
1.123; 95% CI 0.46–1.205) and OS (P = 0.001; hazard ratio =
1149; 95% CI 1.062–1.243).
discussion
This study describes the histological tumor response patterns
of HCRM to chemotherapy, establishes a simple five-point
scoring system to quantify the response as a TRG, shows that
the TRG is related to the type of chemotherapy, and establishes
a correlation between the histological response and survival in
a large series of patients who underwent neo-adjuvant
chemotherapy before liver resection.
Preoperative chemotherapy has gained an important place in
the management of HCRM this last decade [1–3]. It improves
the survival of patients with resectable lesions and helps to
convert a proportion of patients with initially unresectable
disease to a resectable status [5–7, 10]. Response to
chemotherapy in HCRM, however, has been mainly reported as
a variation in the radiological size of the tumor, which evaluates
mostly tumor shrinkage [11] and little is known on the
underlying histological changes, unlike other cancers, where
a TRG has been defined and evaluated clinically [16–18, 20]. The
present investigation is to our knowledge the first one to address
the question of the histological response to chemotherapy in
a large series of patients, and has clarified several points.
First, we observed that the dominant morphological feature
of untreated HCRM was the presence of large areas of viable
tumor glands intermingled with zones of dirty necrosis, with
absent or minor regions of fibrosis, always outgrown by tumor
glands. In contrast, response to chemotherapy corresponded
to a fibrotic involution of the HCRM characterized by a decrease
in the number or complete disappearance of tumor glands,
a reduction of the amount of necrosis, and the appearance or an
increase of fibrosis. This supports the concept that necrosis in
HCRM is more likely related to spontaneous phenomena
involving insufficient vascular supply of the tumor, while the
cytotoxic effects of chemotherapy are mediated by other
mechanisms such as apoptosis [21].
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Figure 2. Disease-free survival of 106 patients with complete clinical
follow-up and with major (MjHR), partial (PHR), or no (NHR)
histological tumor response in liver colorectal metastasis after
neo-adjuvant chemotherapy.
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Figure 3. Overall survival of 106 patients with complete clinical follow-
up and major (MjHR), partial (PHR), or no (NHR) histological tumor
response in liver colorectal metastasis treated by neo-adjuvant
chemotherapy and surgery. P < 0.005.
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In most HCRM, necrosis or fibrosis predominated at the
center while viable tumor glands were mainly located at
the periphery. This pattern was more prominent after
chemotherapy, often with a spiculated configuration at the
borders of the lesion, where viable tumor cells intermingled with
non-tumoral liver tissue. A scattered distribution of the
response throughout the metastasis or a concentric pattern with
viable cells at the center of the mass was never observed in our
series. The presence of viable tumor cells at the periphery of the
HCRM could be explained by the effect of high hydrostatic
intratumoral pressure on the efficacy of drug diffusion [22].
On a practical side, the finding of viable cells at the periphery
even in cases of MjHR should be taken into account in deciding
the surgical safety margin around a lesion, and may explain the
limits of single-needle radio frequency tumor ablation for
HCRM [23].
We observed no significant correlation between the diameter
of metastases and the TRG or with the percentage of necrosis.
For HCRM <1 cm in patients treated with chemotherapy, 76.2%
had persistent viable tumor glands, and 25% had major amount
of tumor cells (TRG4 or TRG5). In addition, despite the relative
frequency of MjHR with oxaliplatin, complete sterilization of
the tumors was rare (4.5% of patients). The above-mentioned
findings argue for surgical removal of all known lesions even if
they have disappeared or appear extinct on morphological or
functional imaging as recently published [24]. The persistence
of viable tumor cells in such minute lesions may require
chemotherapy to be stopped before the metastases can no longer
be localized, and argues against the practice of some centers of
not pursuing such small foci of disease [25].
The TRG was mostly equivalent in the different HCRM of
the same patient, suggesting that the factors that influence
response to chemotherapy are homogeneously represented in all
lesions. Discrepancies in the histological pattern of response
were rare (10%), a finding that renders classification of the
tumor regression meaningful and that allows
clinicopathological correlation.
The TRG grading system used in the present investigation
is based on the Mandard scheme elaborated for esophageal
carcinoma [16] and applied to rectal tumors [17, 18]. The
correlation of the TRG with survival suggests its validity as
a prognostic marker and we propose to implement it in
pathological reports.
A second objective of our study was to evaluate the degree
of histological response in relation to different chemotherapy
regimens. We observed histological tumor regression in 56%
of patients treated by chemotherapy in contrast to preoperative
untreated patients (0%), but results varied widely according
to the regimens. With oxaliplatin, >80% of patients had
a histological tumor regression in their HCRM. Complete
response with no residual tumor cells in all the metastases
within a same patient was rare and only observed after
oxaliplatin-based chemotherapy. In patients treated with
irinotecan/5-FU, there was no significant increase in the
proportion of patients with histological regression compared
with 5-FU-treated patient, but there was a significant decrease in
the amount of intratumoral necrosis. This observation suggests
that radiological tumor shrinkage observed with irinotecan
could be in part related to a decrease in necrotic areas, more
than to disappearance of tumor cells. In these cases, the
favorable prognostic significance of decrease in tumor size could
be due to having rendered resection possible.
Tumor downstaging has been regarded as a marker of radio-
or chemosensitivity and as an important prognostic factor [17,
18, 20, 26–28]. More precisely, our study indicates that MjHR
has a better 5-year DFS and OS than NHR. Multivariate analysis
confirmed TRG as an independent prognostic factor for DFS
and OS, independently from the type of chemotherapy used.
Finally, we reported recently a high prevalence of sinusoidal
obstruction syndrome, related in particular to the use of
oxaliplatin [19]. We found no correlation between the degree of
tumor regression in HCRM and the severity of SOS lesions.
In conclusion, the histological tumor regression of HCRM to
chemotherapy corresponds to fibrosis overgrowth and not to an
increase of necrosis. Oxaliplatin adds substantial efficacy to 5-
FU and irinotecan regimens in terms of histological tumoral
regression. MjHR appears to be associated with DFS and MjHR
or PHR to OS. The small number of patients achieving
a complete tumor response supports the use of surgery for all
patients with HCRM including those who have responded to
neo-adjuvant chemotherapy with no apparent disease on
medical imaging. Although radiological assessment of tumor
response to neo-adjuvant chemotherapy is essential for
evaluating the surgical resectability of HCRM, we suggest that
the TRG grading described in the present study should be
integrated in studies evaluating chemotherapy regimens for
colorectal metastases and be validated in prospective
investigations.
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